Market Cap: $2.35B
CI
Celldex Therapeutics, Inc.
CLDX
NASDAQ (NASDAQ Capital Market)USD
Market Cap: $2.35B
Celldex Therapeutics (Ticker: CLDX) showcases its commitment to innovation in the management of allergic conditions with new long-term data on barzolvolimab for chronic spontaneous urticaria. At a rec…
Celldex Therapeutics (Ticker: CLDX) announces significant advancements in its therapeutic pipeline, particularly marked by long-term results from its Phase 2 trial of barzolvolimab, aimed at treating…
Celldex Therapeutics (Ticker: CLDX) advances its position in the biopharmaceutical sector with significant upcoming presentations poised to impact its growth trajectory. At the forefront of this initi…
Celldex Therapeutics Advances in Immuno-Oncology Amid Market Recovery Celldex Therapeutics, a leader in developing innovative immuno-oncology therapies, focuses on enhancing patient outcomes through g…
Celldex Therapeutics Navigates a Diverse Analyst Landscape Amidst Clinical Advancements Celldex Therapeutics is currently at a pivotal moment as it receives a mix of analyst ratings that reflect a bro…
Celldex Therapeutics Advances Eosinophilic Esophagitis Treatment with Barzolvolimab Results Celldex Therapeutics, Inc. announces significant progress in its clinical research on barzolvolimab, a treat…
Celldex Therapeutics Advances in Eosinophilic Esophagitis Treatment Celldex Therapeutics, Inc. (CLDX) makes significant strides in the biotechnology sector with the announcement of topline results fro…
Celldex Therapeutics: A Mixed Bag of Analyst Perspectives on Future Prospects In recent months, Celldex Therapeutics (CLDX) finds itself at the center of a diverse array of analyst ratings, reflecting…
Celldex Therapeutics Receives Positive Rating from Morgan Stanley Amid Promising Pipeline Celldex Therapeutics, a biopharmaceutical company specializing in immuno-oncology therapies, garners attention…